Contineum Therapeutics Inc (CTNM) Stock Price, Quote & News

Company Profile

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 333 5280

Website: www.contineum-tx.com

Address:

3565 General Atomics Court, Suite 200, San Diego, United States

OfficialStocktwitsUser May. 11 at 1:14 PM

$CTNM RSI: 59.04, MACD: 0.3232 Vol: 0.81, MA20: 13.32, MA50: 13.36 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

OpenOutcrier May. 1 at 12:18 PM

$CTNM (+3.0% pre) Contineum reports positive phase 1b data for chronic pain drug PIPE-791 https://ooc.bz/l/100735

0 · Reply

Merlintrader May. 1 at 8:13 AM

$CTNM Contineum Therapeutics (Nasdaq: $CTNM): PIPE-791 Puts Chronic Pain Back on the Map https://www.merlintrader.com/contineum-therapeutics-may2026-deepdive/

0 · Reply

focafoca99 Apr. 30 at 8:59 PM

$CTNM Contineum reported positive topline data from the exploratory PIPE-791 Phase 1b trial in chronic pain.

0 · Reply

gata2016 Apr. 8 at 2:06 PM

$CABA Less than 2 weeks until Phase 2 announcement. Hope you got in early! $OCGN $CTNM $KYTX

2 · Reply

gata2016 Mar. 25 at 2:01 PM

$CABA Im trying to tell you. Good news it right around the corner. Better get in at a premium! $CTNM $IBRX $TERN

0 · Reply

gata2016 Mar. 23 at 7:42 PM

$CABA Book it. "Yes, it is highly likely—almost standard practice—for a biotechnology company to schedule a conference call, webcast, or investor event to release positive clinical trial data. In RESET-MG, data will be presented in an oral presentation at 1:24 p.m. CDT on Monday, April 20, 2026" $CTNM $SANA $ADVM

4 · Reply

OwenLambert Mar. 19 at 6:47 PM

$CTNM biotech setup with real asymmetry and the move only matters if buyers keep pressing the ask

0 · Reply

char13 Mar. 17 at 9:43 AM

Good morning. Early movers premarket $WNM.X 28m play which sells food in China $CTNM 500m biopharma play $JVA 20m market cap and operating in the coffee industry

0 · Reply

focafoca99 Mar. 4 at 12:20 AM

$CTNM has an upcoming investor stage... will they drop enough color to wake up this stock?

0 · Reply

Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference

May 11, 2026, 4:05 PM EDT - 1 day ago

Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference

ATS

May 5, 2026, 4:05 PM EDT - 7 days ago

Contineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones

May 1, 2026, 4:05 PM EDT - 11 days ago

Contineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-04-30T20:30:37.000Z - 12 days ago

Contineum reports positive topline data from exploratory PIPE-791 Phase 1b

Apr 30, 2026, 4:05 PM EDT - 12 days ago

Contineum Therapeutics Reports Positive Topline Data From Its Exploratory PIPE-791 Phase 1b Trial in Chronic Pain

Mar 13, 2026, 4:05 PM EDT - 2 months ago

Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mar 11, 2026, 2:20 PM EDT - 2 months ago

Contineum Therapeutics Transcript: Leerink Global Healthcare Conference 2026

2026-03-06T11:41:29.000Z - 2 months ago

Contineum price target raised to $20 from $14 at Baird

2026-03-05T21:25:30.000Z - 2 months ago

Contineum reports Q4 EPS (49c), consensus (39c)

Mar 5, 2026, 4:05 PM EST - 2 months ago

Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones

Mar 3, 2026, 4:05 PM EST - 2 months ago

Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference

2026-01-08T11:20:26.000Z - 4 months ago

Contineum downgraded to Equal Weight from Overweight at Morgan Stanley

Dec 11, 2025, 10:24 PM EST - 5 months ago

Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering

Dec 11, 2025, 4:05 PM EST - 5 months ago

Contineum Therapeutics Announces Proposed $75.0 Million Public Offering

Dec 3, 2025, 1:20 PM EST - 5 months ago

Contineum Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 24, 2025, 4:05 PM EST - 6 months ago

Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference

2025-11-24T12:35:20.000Z - 6 months ago

Contineum price target lowered to $14 from $16 at Baird

2025-11-21T13:45:20.000Z - 6 months ago

Contineum price target lowered to $22 from $25 at RBC Capital

2025-11-20T21:30:20.000Z - 6 months ago

Contineum Therapeutics Inc trading resumes

2025-11-20T21:10:35.000Z - 6 months ago

Contineum Phase 2 VISTA trial did not meet primary, secondary endpoints

2025-11-20T21:06:19.000Z - 6 months ago

Contineum Therapeutics Inc trading halted, news pending

Nov 20, 2025, 4:05 PM EST - 6 months ago

Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

2025-10-30T20:27:43.000Z - 6 months ago

Contineum reports Q3 EPS (45c), consensus (46c)

Oct 30, 2025, 4:05 PM EDT - 6 months ago

Contineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones

2025-09-25T10:25:52.000Z - 8 months ago

Leerink bullish on Contineum, initiates with an Outperform

BMY

2025-09-25T10:10:38.000Z - 8 months ago

Contineum initiated with an Outperform at Leerink

2025-09-18T12:55:38.000Z - 8 months ago

Contineum announces topline data from PIPE-791 trial

Sep 18, 2025, 8:05 AM EDT - 8 months ago

Contineum Therapeutics Reports Positive Topline Data From Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

Sep 9, 2025, 2:00 PM EDT - 8 months ago

Contineum Therapeutics Transcript: Baird Global Healthcare Conference 2025

Sep 8, 2025, 8:30 AM EDT - 8 months ago

Contineum Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 4, 2025, 9:10 AM EDT - 8 months ago

Contineum Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Aug 28, 2025, 4:05 PM EDT - 9 months ago

Contineum Therapeutics to Present at September Investor Conferences

Aug 5, 2025, 4:05 PM EDT - 10 months ago

Contineum Therapeutics Reports Second-Quarter 2025 Financial Results; Updates Key Clinical Development Milestones

2025-06-25T12:35:55.000Z - 11 months ago

Contineum completes enrollment for cohorts of PIPE-791 trial

Jun 25, 2025, 8:15 AM EDT - 11 months ago

Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

2025-06-18T20:20:36.000Z - 11 months ago

Contineum initiated with an Outperform at William Blair

May 20, 2025, 8:30 AM EDT - 1 year ago

Contineum Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 15, 2025, 4:05 PM EDT - 1 year ago

Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference

May 14, 2025, 4:05 PM EDT - 1 year ago

Contineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones

Apr 28, 2025, 4:05 PM EDT - 1 year ago

Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development

Mar 18, 2025, 12:30 PM EDT - 1 year ago

Contineum Therapeutics Transcript: Stifel 2025 Virtual CNS Forum

Mar 17, 2025, 4:05 PM EDT - 1 year ago

Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors

Mar 12, 2025, 4:05 PM EDT - 1 year ago

Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum

Mar 11, 2025, 3:00 PM EDT - 1 year ago

Contineum Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Mar 6, 2025, 4:05 PM EST - 1 year ago

Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones

Mar 4, 2025, 4:05 PM EST - 1 year ago

Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791

Mar 3, 2025, 4:05 PM EST - 1 year ago

Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference

Jan 8, 2025, 4:05 PM EST - 1 year ago

Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

Dec 16, 2024, 4:05 PM EST - 1 year ago

Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

Dec 4, 2024, 11:15 AM EST - 1 year ago

Contineum Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Nov 25, 2024, 8:05 AM EST - 1 year ago

Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference

Nov 18, 2024, 4:10 PM EST - 1 year ago

Contineum Therapeutics Transcript: Stifel 2024 Healthcare Conference

Nov 18, 2024, 8:05 AM EST - 1 year ago

Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain

Nov 13, 2024, 4:05 PM EST - 1 year ago

Contineum Therapeutics to Attend Upcoming Investor Conferences

Nov 6, 2024, 4:05 PM EST - 1 year ago

Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Sep 10, 2024, 2:30 PM EDT - 1 year ago

Contineum Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 4, 2024, 7:00 AM EDT - 1 year ago

Contineum Therapeutics Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 28, 2024, 4:05 PM EDT - 1 year ago

Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple Sclerosis

Jun 24, 2024, 4:05 PM EDT - 2 years ago

Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

RNA

Jun 10, 2024, 8:40 AM EDT - 2 years ago

Contineum Therapeutics Transcript: 45th Annual Global Healthcare Conference

Jun 4, 2024, 4:05 PM EDT - 2 years ago

Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference

Jun 3, 2024, 4:05 PM EDT - 2 years ago

Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary

May 20, 2024, 4:05 PM EDT - 2 years ago

Contineum Therapeutics Announces Appointment of Troy Ignelzi to Board of Directors

May 16, 2024, 4:05 PM EDT - 2 years ago

Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Apr 4, 2024, 9:02 PM EDT - 2 years ago

Contineum Therapeutics Announces Pricing of Initial Public Offering

OfficialStocktwitsUser May. 11 at 1:14 PM

0 · Reply

OpenOutcrier May. 1 at 12:18 PM

$CTNM (+3.0% pre) Contineum reports positive phase 1b data for chronic pain drug PIPE-791 https://ooc.bz/l/100735

0 · Reply

Merlintrader May. 1 at 8:13 AM

$CTNM Contineum Therapeutics (Nasdaq: $CTNM): PIPE-791 Puts Chronic Pain Back on the Map https://www.merlintrader.com/contineum-therapeutics-may2026-deepdive/

0 · Reply

focafoca99 Apr. 30 at 8:59 PM

$CTNM Contineum reported positive topline data from the exploratory PIPE-791 Phase 1b trial in chronic pain.

0 · Reply

gata2016 Apr. 8 at 2:06 PM

$CABA Less than 2 weeks until Phase 2 announcement. Hope you got in early! $OCGN $CTNM $KYTX

2 · Reply

gata2016 Mar. 25 at 2:01 PM

$CABA Im trying to tell you. Good news it right around the corner. Better get in at a premium! $CTNM $IBRX $TERN

0 · Reply

gata2016 Mar. 23 at 7:42 PM

4 · Reply

OwenLambert Mar. 19 at 6:47 PM

$CTNM biotech setup with real asymmetry and the move only matters if buyers keep pressing the ask

0 · Reply

char13 Mar. 17 at 9:43 AM

Good morning. Early movers premarket $WNM.X 28m play which sells food in China $CTNM 500m biopharma play $JVA 20m market cap and operating in the coffee industry

0 · Reply

focafoca99 Mar. 4 at 12:20 AM

$CTNM has an upcoming investor stage... will they drop enough color to wake up this stock?

0 · Reply

BillionerOfKing Feb. 26 at 3:24 PM

$CTNM Current Stock Price: $15.76 Contracts to trade: $15.0 CTNM Mar 20 2026 Call Entry: $0.30 Exit: $0.53 ROI: 77% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

OfficialStocktwitsUser Feb. 17 at 8:57 PM

$CTNM RSI: 55.51, MACD: 0.8291 Vol: 1.10, MA20: 14.21, MA50: 12.50 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

gata2016 Feb. 12 at 3:01 PM

$CABA loved what I just heard a good data coming in! $CTNM $KYTX don't miss the boat on this.

1 · Reply

ClayClymer689 Feb. 11 at 3:35 PM

$CTNM Contineum Therapeutics; biotech focused on neuroscience and inflammation; early-stage pipeline; binary clinical catalysts ahead.

0 · Reply

kaoz Feb. 11 at 3:04 PM

$CTNM failed primary. Yikes. Someone’s pumping so big boys can dump on retail.

0 · Reply

HODLHotshot Feb. 4 at 4:05 PM

$CTNM is a technology or media company; without specifics, analysis would focus on its business model, growth trajectory, and competitive moat.

0 · Reply

BillionerOfKing Feb. 3 at 9:40 PM

$CTNM Current Stock Price: $15.24 Contracts to trade: $15.0 CTNM Feb 20 2026 Call Entry: $0.72 Exit: $1.15 ROI: 60% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

squiggleburp Jan. 16 at 2:09 PM

$CTNM Okay dokey, another 12 percent honk to the PL…. Very small position though. I never listen to myself..

0 · Reply

squiggleburp Jan. 13 at 6:07 PM

$CTNM who like squiggle dancing? I am here, have no fear…

0 · Reply

topstockalerts Jan. 13 at 5:38 PM

$CTNM Big move developing as buyers pile in 😮. Price is moving with force. This is real momentum.

0 · Reply

garygb Jan. 6 at 5:23 PM

$CTNM Buying opportunity.

0 · Reply

gata2016 Jan. 6 at 2:17 PM

$CABA For my fellow investors at $CTNM and $KYTX CABA is another in my portfolio worth a look. All three have a great deal of upside potential. Just playing the waiting game now.

0 · Reply

Market Cap	510.32M
Revenue (ttm)	0.00
Net Income (ttm)	-59.98M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	126,400
Avg Vol	304,140
Day's Range	N/A - N/A
Shares Out	37.39M
Stochastic %K	49%
Beta	0.89
Analysts	Strong Sell
Price Target	$21.83